THE HELLENIC THORACIC SOCIETY ( HTS ) THE GREEK BRONCHOLOGIC SOCIETY ( GBS )

An structured abstract should be provided of not more than 250 words. It should consist of four paragraphs, labelled Background, Methods, Results, and Conclusions. They should briefly describe, respectively, the problem being addressed in the study, how the study was performed, the most important results, and what the authors conclude from the results. Up to 5 key words should be added taken, from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list at http://www.nlm.nih.gov/mesh/ meshhome.html. Text. The paper should nclude the following sections:

[1]  E. Alexopoulos,et al.  The cost of COPD exacerbations: a university hospital--based study in Greece. , 2011, Respiratory medicine.

[2]  R. Davies,et al.  The Approach to the Patient with a Parapneumonic Effusion , 2010, Seminars in respiratory and critical care medicine.

[3]  K. Kostikas,et al.  COPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry program. , 2010, Primary care respiratory journal : journal of the General Practice Airways Group.

[4]  W. Freeman,et al.  Age-related changes in the expression and oxidation of bronchoalveolar lavage proteins in the rat. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[5]  H. Haagsman,et al.  Toxic oxidant species and their impact on the pulmonary surfactant system , 2009, Lung.

[6]  Xiaoxuan Guo,et al.  Ablation of SP-A has a negative impact on the susceptibility of mice to Klebsiella pneumoniae infection after ozone exposure: sex differences , 2008, Respiratory research.

[7]  Á. D. de Miguel,et al.  Determinants and predictors of the cost of COPD in primary care: A Spanish perspective , 2008, International journal of chronic obstructive pulmonary disease.

[8]  M. Roslina,et al.  Compliance to national guidelines on the management of chronic obstructive pulmonary disease in Malaysia: a single centre experience. , 2008, Singapore medical journal.

[9]  C. Tu,et al.  A 30-Month Experience of Thoracic Empyema in a Tertiary Hospital: Emphasis on Differing Bacteriology and Outcome Between the Medical Intensive Care Unit (MICU) and Medical Ward , 2008, Southern medical journal.

[10]  M. Surette,et al.  The Streptococcus milleri group—An unrecognized cause of disease in cystic fibrosis: A case series and literature review , 2008, Pediatric pulmonology.

[11]  R. Davies,et al.  Effusions from infections: parapneumonic effusions and empyema , 2008 .

[12]  Shahin Barakat,et al.  Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease , 2008, International journal of chronic obstructive pulmonary disease.

[13]  F. Petersen,et al.  LuxS and expression of virulence factors in Streptococcus intermedius. , 2007, Oral microbiology and immunology.

[14]  H. Nagamune,et al.  Histone‐like DNA binding protein of Streptococcus intermedius induces the expression of pro‐inflammatory cytokines in human monocytes via activation of ERK1/2 and JNK pathways , 2007, Cellular microbiology.

[15]  A. de Haan,et al.  The clinical utility of the GOLD classification of COPD disease severity in pulmonary rehabilitation. , 2008, Respiratory medicine.

[16]  Guirong Wang,et al.  Impact of ozone exposure on the phagocytic activity of human surfactant protein A (SP-A) and SP-A variants. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[17]  C. Tu,et al.  Community-Acquired Thoracic Empyema in Young Adults , 2007, Southern medical journal.

[18]  C. Tu,et al.  An urgent problem of aerobic gram-negative pathogen infection in complicated parapneumonic effusions or empyemas. , 2007, Internal medicine.

[19]  N. Ahmed,et al.  AI-2 quorum sensing affects antibiotic susceptibility in Streptococcus anginosus. , 2007, The Journal of antimicrobial chemotherapy.

[20]  W. M. Foster,et al.  Ozone and pulmonary innate immunity. , 2007, Proceedings of the American Thoracic Society.

[21]  A. E. El Solh,et al.  Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. , 2007, American journal of respiratory and critical care medicine.

[22]  Xiaoxuan Guo,et al.  Role of surfactant protein-A (SP-A) in lung injury in response to acute ozone exposure of SP-A deficient mice. , 2007, Toxicology and applied pharmacology.

[23]  Guirong Wang,et al.  Surfactant Protein A2 (SP-A2) Variants Expressed in CHO Cells Stimulate Phagocytosis of Pseudomonas aeruginosa More than Do SP-A1 Variants , 2007, Infection and Immunity.

[24]  W. T. McNicholas,et al.  Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities , 2006, European Respiratory Journal.

[25]  S. Matalon,et al.  Surfactant dysfunction in SP-A-/- and iNOS-/- mice with mycoplasma infection. , 2007, American journal of respiratory cell and molecular biology.

[26]  T. Marrie,et al.  Thoracic empyema in patients with community-acquired pneumonia. , 2006, The American journal of medicine.

[27]  R. Davies,et al.  The bacteriology of pleural infection by genetic and standard methods and its mortality significance. , 2006, American journal of respiratory and critical care medicine.

[28]  B. Monz,et al.  Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? , 2006, Chest.

[29]  J. Kirby,et al.  Toll-like receptor (TLR) response tolerance: a key physiological "damage limitation" effect and an important potential opportunity for therapy. , 2006, Current medicinal chemistry.

[30]  N. Siafakas,et al.  Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece* , 2006, Current medical research and opinion.

[31]  M. Bilgin,et al.  BENEFITS OF EARLY AGGRESSIVE MANAGEMENT OF EMPYEMA THORACIS , 2006, ANZ journal of surgery.

[32]  J. Wiener-Kronish,et al.  Surfactant proteins A and D enhance pulmonary clearance of Pseudomonas aeruginosa. , 2006, American journal of respiratory cell and molecular biology.

[33]  M. Wlodarski,et al.  Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. , 2005, Blood.

[34]  C. Tu,et al.  The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit , 2006, Intensive Care Medicine.

[35]  Kostas Spiropoulos,et al.  Global Initiative for Chronic Obstructive Pulmonary Disease Statement and Health-Related Quality of Life , 2005 .

[36]  N. Frossard,et al.  Exposure to Endotoxins during Sensitization Prevents Further Endotoxin-Induced Exacerbation of Airway Inflammation in a Mouse Model of Allergic Asthma , 2005, International Archives of Allergy and Immunology.

[37]  K. Kida,et al.  Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. , 2005, Respiratory medicine.

[38]  R. Davies,et al.  U.K. Controlled trial of intrapleural streptokinase for pleural infection. , 2005, The New England journal of medicine.

[39]  B. Chandrasekar,et al.  Interleukin-18 Is a Pro-hypertrophic Cytokine That Acts through a Phosphatidylinositol 3-Kinase-Phosphoinositide-dependent Kinase-1-Akt-GATA4 Signaling Pathway in Cardiomyocytes* , 2005, Journal of Biological Chemistry.

[40]  R. Scrivo,et al.  Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. , 2005, The Journal of rheumatology.

[41]  J. Finkelstein,et al.  SEQUENTIAL EXPOSURES TO OZONE AND LIPOPOLYSACCHARIDE IN POSTNATAL LUNG ENHANCE OR INHIBIT CYTOKINE RESPONSES , 2005, Experimental Lung Research.

[42]  E. Stobberingh,et al.  Hydrolytic enzymes ofStreptococcus anginosus, Streptococcus constellatus andStreptococcus intermedius in relation to infection , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[43]  S. Ichiyama,et al.  Feasibility of flow cytometry for the detection of bacteria from body fluid samples , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[44]  Samuel I. Miller,et al.  LPS, TLR4 and infectious disease diversity , 2005, Nature Reviews Microbiology.

[45]  J. Floros,et al.  SP-A1 and SP-A2 variants differentially enhance association of Pseudomonas aeruginosa with rat alveolar macrophages. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[46]  K. Harris,et al.  Empyema: the use of broad range 16S rDNA PCR for pathogen detection , 2004, Archives of Disease in Childhood.

[47]  A. Gow,et al.  Enhanced Lung Injury and Delayed Clearance of Pneumocystis carinii in Surfactant Protein A-Deficient Mice: Attenuation of Cytokine Responses and Reactive Oxygen-Nitrogen Species , 2004, Infection and Immunity.

[48]  J. Floros,et al.  Factors affecting SP-A-mediated phagocytosis in human monocytic cell lines. , 2004, Respiratory medicine.

[49]  L. Ochoa,et al.  The changing face of pleural empyemas in children: epidemiology and management. , 2004, Pediatrics.

[50]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[51]  Guirong Wang,et al.  Differences in biochemical properties and in biological function between human SP-A1 and SP-A2 variants, and the impact of ozone-induced oxidation. , 2004, Biochemistry.

[52]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[53]  Guirong Wang,et al.  Human SP-A genetic variants and bleomycin-induced cytokine production by THP-1 cells: effect of ozone-induced SP-A oxidation. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[54]  S. Matalon,et al.  Role of surfactant protein-A in nitric oxide production and mycoplasma killing in congenic C57BL/6 mice. , 2004, American journal of respiratory cell and molecular biology.

[55]  J. Hardie,et al.  Interactions between Eikenella corrodens and ‘Streptococcus milleri-group’ organisms: possible mechanisms of pathogenicity in mixed infections , 1996, Antonie van Leeuwenhoek.

[56]  K. Katsouyanni,et al.  Air pollution in relation to manifestations of chronic pulmonary disease: A nested case–control study in Athens, Greece , 2004, European Journal of Epidemiology.

[57]  J. Alcorn,et al.  Surfactant protein A inhibits alveolar macrophage cytokine production by CD14-independent pathway. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[58]  J. Wright,et al.  Surfactant protein A enhances apoptotic cell uptake and TGF-beta1 release by inflammatory alveolar macrophages. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[59]  D. Phelps,et al.  Surfactant protein A increases matrix metalloproteinase-9 production by THP-1 cells. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[60]  F. Rengo,et al.  Do GOLD stages of COPD severity really correspond to differences in health status? , 2003, European Respiratory Journal.

[61]  D. Lacey,et al.  Surfactant protein A is a required mediator of keratinocyte growth factor after experimental marrow transplantation. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[62]  J. Harkema,et al.  Ozone exposure enhances endotoxin-induced mucous cell metaplasia in rat pulmonary airways. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[63]  J. Wright.  Pulmonary surfactant: a front line of lung host defense. , 2003, The Journal of clinical investigation.

[64]  P. Lavie,et al.  Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. , 2003, American journal of respiratory and critical care medicine.

[65]  E. Clini,et al.  Impact of comprehensive pulmonary rehabilitation on anxiety and depression in hospitalized COPD patients. , 2003, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[66]  S. Matalon,et al.  Inhibition of human surfactant protein A function by oxidation intermediates of nitrite. , 2002, Free radical biology & medicine.

[67]  R. Facklam,et al.  What Happened to the Streptococci: Overview of Taxonomic and Nomenclature Changes , 2002, Clinical Microbiology Reviews.

[68]  M. Walport,et al.  Role of Surfactant Proteins A, D, and C1q in the Clearance of Apoptotic Cells In Vivo and In Vitro: Calreticulin and CD91 as a Common Collectin Receptor Complex1 , 2002, The Journal of Immunology.

[69]  I. Y. Haddad,et al.  Surfactant protein A decreases lung injury and mortality after murine marrow transplantation. , 2002, American journal of respiratory cell and molecular biology.

[70]  D. Miller,et al.  Health-related quality of life , 2002, Multiple sclerosis.

[71]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[72]  T. Korfhagen,et al.  Surfactant protein A regulates surfactant phospholipid clearance after LPS-induced injury in vivo. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[73]  R. Murphy,et al.  Oxidized phospholipids derived from ozone-treated lung surfactant extract reduce macrophage and epithelial cell viability. , 2002, Chemical research in toxicology.

[74]  J. Whitsett,et al.  Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[75]  Guirong Wang,et al.  In Vitro Exposure of Proteins to Ozone , 2002, Toxicology mechanisms and methods.

[76]  J. Finkelstein,et al.  ENDOTOXIN POTENTIATES OZONE-INDUCED PULMONARY CHEMOKINE AND INFLAMMATORY RESPONSES , 2002, Experimental lung research.

[77]  L. Kemény,et al.  CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis , 2002, Clinical and experimental immunology.

[78]  Guirong Wang,et al.  The effect of ozone exposure on the ability of human surfactant protein a variants to stimulate cytokine production. , 2001, Environmental health perspectives.

[79]  D. Musher,et al.  Interaction between human polymorphonuclear leukocytes and Streptococcus milleri group bacteria. , 2002, The Journal of infectious diseases.

[80]  W. Watford,et al.  Surfactant Protein A Regulates Complement Activation1 , 2001, The Journal of Immunology.

[81]  A. Koch,et al.  A Novel Role for Interleukin-18 in Adhesion Molecule Induction through NFκB and Phosphatidylinositol (PI) 3-Kinase-dependent Signal Transduction Pathways* , 2001, The Journal of Biological Chemistry.

[82]  Margot Thome,et al.  Regulation of lymphocyte proliferation and death by flip , 2001, Nature Reviews Immunology.

[83]  K. Chin,et al.  Acute effect of nasal continuous positive airway pressure therapy on the systemic immunity of patients with obstructive sleep apnea syndrome. , 2001, Sleep.

[84]  I. Kim,et al.  Dithiothreitol induces the sacrificial antioxidant property of human serum albumin in a metal-catalyzed oxidation and gamma-irradiation system. , 2001, Archives of biochemistry and biophysics.

[85]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[86]  Hye-Youn Cho,et al.  Toll-like receptor 4 mediates ozone-induced murine lung hyperpermeability via inducible nitric oxide synthase. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[87]  D. Phelps.  Surfactant Regulation of Host Defense Function in the Lung: A Question of Balance , 2001, Pediatric pathology & molecular medicine.

[88]  E. Crouch,et al.  Surfactant proteins a and d and pulmonary host defense. , 2001, Annual review of physiology.

[89]  Mingchen Song,et al.  Interaction of Surfactant Protein A with Lipopolysaccharide and Regulation of Inflammatory Cytokines in the THP-1 Monocytic Cell Line , 2000, Infection and Immunity.

[90]  M. Selman,et al.  Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase-1 expression. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[91]  B. Littenberg,et al.  Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. , 2000, Chest.

[92]  Guirong Wang,et al.  Human SP-A protein variants derived from one or both genes stimulate TNF-alpha production in the THP-1 cell line. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[93]  S. Reddy,et al.  Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. , 2000, American journal of respiratory cell and molecular biology.

[94]  G H Guyatt,et al.  Long-term effects of outpatient rehabilitation of COPD: A randomized trial. , 2000, Chest.

[95]  T. Goto,et al.  Distribution of the Intermedilysin Gene among the Anginosus Group Streptococci and Correlation between Intermedilysin Production and Deep-Seated Infection with Streptococcus intermedius , 2000, Journal of Clinical Microbiology.

[96]  C. Figdor,et al.  H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. , 1999, Journal of immunology.

[97]  Takai,et al.  Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA) , 1999, Clinical and experimental immunology.

[98]  N. Adair,et al.  Exercise rehabilitation and chronic obstructive pulmonary disease stage. , 1999, American journal of respiratory and critical care medicine.

[99]  D. Voelker,et al.  Binding of Rat and Human Surfactant Proteins A and D to Aspergillus fumigatus Conidia , 1999, Infection and Immunity.

[100]  A. Takao,et al.  Abscess Forming Ability of Streptococcus milleri Group: Synergistic Effect with Fusobacterium nucleatum , 1999, Microbiology and immunology.

[101]  W. Watford,et al.  Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice. , 1999, American journal of respiratory cell and molecular biology.

[102]  F. Gleeson,et al.  Predictors of outcome and long-term survival in patients with pleural infection. , 1999, American journal of respiratory and critical care medicine.

[103]  A. Keshavarzian,et al.  Determination of protein carbonyl groups by immunoblotting. , 1999, Analytical biochemistry.

[104]  J. Whitsett,et al.  Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. , 1998, American journal of respiratory cell and molecular biology.

[105]  Müller,et al.  Effect of air pollutants on the pulmonary surfactant system , 1998, European journal of clinical investigation.

[106]  M. Salavert,et al.  Thoracic infection caused by Streptococcus milleri. , 1998, The European respiratory journal.

[107]  S. Uhlig,et al.  Early alterations in intracellular and alveolar surfactant of the rat lung in response to endotoxin. , 1998, American journal of respiratory and critical care medicine.

[108]  T. Proft,et al.  Superantigens: Just Like Peptides Only Different , 1998, The Journal of experimental medicine.

[109]  G. Enhorning,et al.  Ozone affects breathing and pulmonary surfactant function in mice. , 1998, Toxicology.

[110]  S. Matalon,et al.  Nitrated SP-A does not enhance adherence of Pneumocystis carinii to alveolar macrophages. , 1998, The American journal of physiology.

[111]  T. Ezaki,et al.  Determination of 23S rRNA sequences from members of the genus Streptococcus and characterization of genetically distinct organisms previously identified as members of the Streptococcus anginosus group. , 1998, FEMS microbiology letters.

[112]  K. Driscoll,et al.  Chemokine regulation of ozone-induced neutrophil and monocyte inflammation. , 1998, The American journal of physiology.

[113]  P. Hsueh,et al.  Empyema thoracis and lung abscess caused by viridans streptococci. , 1997, American journal of respiratory and critical care medicine.

[114]  Diane P. Martin,et al.  Patient-assessed health outcomes in chronic lung disease: what are they, how do they help us, and where do we go from here? , 1997, American journal of respiratory and critical care medicine.

[115]  M. Kitano,et al.  Experimental endocarditis induction and platelet aggregation by Streptococcus anginosus, Streptococcus constellatus and Streptococcus intermedius. , 1997, FEMS immunology and medical microbiology.

[116]  P. Courvalin,et al.  Identification of clinically relevant viridans group streptococci to the species level by PCR , 1997, Journal of clinical microbiology.

[117]  U. Kishore,et al.  Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages , 1997, Infection and immunity.

[118]  S. Kremlev,et al.  Effect of SP-A and surfactant lipids on expression of cell surface markers in the THP-1 monocytic cell line. , 1997, The American journal of physiology.

[119]  R. H. Smith,et al.  A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. , 1997, Journal of immunological methods.

[120]  H. Jenkinson,et al.  Streptococcal adhesion and colonization. , 1997, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[121]  M. Pfaller,et al.  In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci. , 1997, Diagnostic microbiology and infectious disease.

[122]  M. Bachelet,et al.  Modified Natural Porcine Surfactant Inhibits Superoxide Anions and Proinflammatory Mediators Released by Resting and Stimulated Human Monocytes , 1997, Pediatric Research.

[123]  F. Alcaide,et al.  In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients , 1996, Antimicrobial agents and chemotherapy.

[124]  S. Matalon,et al.  Nitration of surfactant protein A (SP-A) tyrosine residues results in decreased mannose binding ability. , 1996, Archives of biochemistry and biophysics.

[125]  D. Hume,et al.  Endotoxin signal transduction in macrophages , 1996, Journal of leukocyte biology.

[126]  L. Schouls,et al.  Rapid species identification of "Streptococcus milleri" strains by line blot hybridization: identification of a distinct 16S rRNA population closely related to Streptococcus constellatus , 1996, Journal of clinical microbiology.

[127]  D. Beighton,et al.  Degradation and utilisation of chondroitin sulphate by Streptococcus intermedius. , 1996, Journal of medical microbiology.

[128]  R. Jones,et al.  The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. , 1996, Diagnostic microbiology and infectious disease.

[129]  R. Prescott,et al.  The clinical course and management of thoracic empyema. , 1996, QJM : monthly journal of the Association of Physicians.

[130]  M. Yasujima,et al.  [Peripheral lymphocyte subset of patients with pancreatic diabetes mellitus--about a decreased ratio of T-LGL and ability of host defense]. , 1996, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[131]  S. Matalon,et al.  Nitration of surfactant protein A results in decreased ability to aggregate lipids. , 1996, The American journal of physiology.

[132]  D. Ohlendorf,et al.  The staphylococcal and streptococcal pyrogenic toxin family. , 1996, Advances in experimental medicine and biology.

[133]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[134]  G. Hook,et al.  Altered regulation of surfactant phospholipid and protein A during acute pulmonary inflammation. , 1995, Biochimica et biophysica acta.

[135]  M. Willcox.  Potential pathogenic properties of members of the "Streptococcus milleri" group in relation to the production of endocarditis and abscesses. , 1995, Journal of medical microbiology.

[136]  K. Ruoff,et al.  Identification of "Streptococcus milleri" group isolates to the species level with a commercially available rapid test system , 1995, Journal of clinical microbiology.

[137]  J. Westwick,et al.  RANTES-activated human T lymphocytes. A role for phosphoinositide 3-kinase. , 1995, Journal of immunology.

[138]  R. Osawa,et al.  Effects of different acidulants on growth of ‘Streptococcus milleri group’ strains isolated from various sites of the human body , 1995, Letters in applied microbiology.

[139]  M. Collins,et al.  "Streptococcus milleri" strains displaying a gliding type of motility. , 1995, International journal of systematic bacteriology.

[140]  A. Saito,et al.  Pathogenicity of the Streptococcus milleri group in pulmonary infections--effect on phagocytic killing by human polymorphonuclear neutrophils. , 1995, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[141]  P. Soeters,et al.  Bacteremia involving the "Streptococcus milleri" group: analysis of 19 cases. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[142]  T. Shinzato,et al.  A mechanism of pathogenicity of "Streptococcus milleri group" in pulmonary infection: synergy with an anaerobe. , 1994, Journal of medical microbiology.

[143]  I. Brook,et al.  Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. , 1993, Chest.

[144]  J. Carter,et al.  Ozone inhalation stimulates expression of a neutrophil chemotactic protein, macrophage inflammatory protein 2. , 1993, Toxicology and applied pharmacology.

[145]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[146]  R. Raz,et al.  [Pyogenic liver abscess caused by Streptococcus milleri]. , 1992, Harefuah.

[147]  R. Mason,et al.  Application of the EPR spin-trapping technique to the detection of radicals produced in vivo during inhalation exposure of rats to ozone. , 1992, Toxicology and applied pharmacology.

[148]  D. Beighton,et al.  Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus (the Streptococcus milleri group): association with different body sites and clinical infections , 1992, Journal of clinical microbiology.

[149]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[150]  P. Jones.  Quality of life measurement for patients with diseases of the airways. , 1991, Thorax.

[151]  M. V. van Greevenbroek,et al.  Structural and functional changes of surfactant protein A induced by ozone. , 1991, The American journal of physiology.

[152]  J. Verhoef,et al.  Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages. , 1991, The American journal of physiology.

[153]  P. Jones,et al.  Long-term reproducibility of Borg scale estimates of breathlessness during exercise. , 1991, Clinical science.

[154]  H. Haagsman,et al.  Synthesis and assembly of lung surfactant. , 1991, Annual review of physiology.

[155]  C. Leport,et al.  Clinical and bacterial features of infections caused by Streptococcus milleri. , 1991, Scandinavian journal of infectious diseases.

[156]  D. Beighton,et al.  Phenotypic differentiation of Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus strains within the "Streptococcus milleri group" , 1990, Journal of clinical microbiology.

[157]  M. Mustafa,et al.  Biochemical basis of ozone toxicity. , 1990, Free radical biology & medicine.

[158]  P. Unsworth,et al.  Hyaluronidase production in Streptococcus milleri in relation to infection. , 1989, Journal of clinical pathology.

[159]  J. Gossling.  Occurrence and pathogenicity of the Streptococcus milleri group. , 1988, Reviews of infectious diseases.

[160]  K. Ruoff.  Streptococcus anginosus ("Streptococcus milleri"): the unrecognized pathogen , 1988, Clinical Microbiology Reviews.

[161]  V. Herson,et al.  Fatal infection in neonates of 26 weeks' gestation due to Streptococcus milleri: report of two cases. , 1987, Journal of clinical pathology.

[162]  J. Dussek,et al.  Streptococcus milleri as a cause of pleural empyema. , 1985, Thorax.

[163]  J. Ratcliffe,et al.  Streptococcus milleri found in pulmonary empyemas and abscesses. , 1985, Journal of clinical pathology.

[164]  C. A. Hart,et al.  Streptococcus milleri in appendicitis in children. , 1985, Journal of pediatric surgery.

[165]  P. van der Auwera.  Clinical significance of Streptococcus milleri. , 1985, European journal of clinical microbiology.

[166]  G. Tillotson,et al.  Antibiotic susceptibilities of clinical strains of Streptococcus milleri and related streptococci. , 1984, The Journal of antimicrobial chemotherapy.

[167]  D. Rhoden,et al.  Evaluation of the Rapid Strep system for the identification of clinical isolates of Streptococcus species , 1984, Journal of clinical microbiology.

[168]  G. Eliopoulos,et al.  Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns , 1983, Antimicrobial Agents and Chemotherapy.

[169]  R. Kapila,et al.  Fatal Streptococcus MG-intermedius (Streptococcus milleri) meningitis in an adult. , 1982, American journal of clinical pathology.

[170]  I. Phillips,et al.  Microbiology of pyogenic liver abscess. , 1982, British medical journal.

[171]  B. Varkey,et al.  Empyema thoracis during a ten-year period. Analysis of 72 cases and comparison to a previous study (1952 to 1967). , 1981, Archives of internal medicine.

[172]  D. Shlaes,et al.  Infections due to Lancefield group F and related Streptococci (S. milleri, S. anginosus). , 1981, Medicine.

[173]  H. Thadepalli,et al.  Rapid diagnosis of anaerobic empyema by direct gas-liquid chromatography of pleural fluid. , 1980, Chest.

[174]  J. de Louvois.  Bacteriological examination of pus from abscesses of the central nervous system. , 1980, Journal of clinical pathology.

[175]  J. Goust,et al.  Evidence for the synthesis and release of strongly immunosuppressive, noncytotoxic substances by Streptococcus intermedius. , 1979, The Journal of clinical investigation.

[176]  W. Wilson,et al.  Antimicrobial susceptibilities of species of viridans streptococci. , 1979, The Journal of infectious diseases.

[177]  P. M. Poole,et al.  Occurrence and cultural features of Streptococcus milleri in various body sites. , 1979, Journal of clinical pathology.

[178]  M. T. Parker,et al.  The cultural and biochemical characters of Streptococcus milleri strains isolated from human sources , 1979, Journal of Hygiene.

[179]  J. Melo,et al.  Brain abscess due to Streptococcus MG-intermedius (Streptococcus milleri) , 1978, Journal of clinical microbiology.

[180]  H. Masur,et al.  Serious infections caused by Streptococcus milleri. , 1978, The American journal of medicine.

[181]  M. Finland,et al.  Changing ecology of acute bacterial empyema: occurrence and mortality at Boston City Hospital during 12 selected years from 1935 to 1972. , 1978, The Journal of infectious diseases.

[182]  P. M. Poole,et al.  Streptococcus milleri in the appendix. , 1977, Journal of clinical pathology.

[183]  R. Facklam.  Physiological differentiation of viridans streptococci , 1977, Journal of clinical microbiology.

[184]  M. T. Parker,et al.  Streptococci and aerococci associated with systemic infection in man. , 1976, Journal of medical microbiology.

[185]  R. Lampe,et al.  Detection of bacterial antigen in pleural fluid by counterimmunoelectrophoresis. , 1976, The Journal of pediatrics.

[186]  J. Bartlett,et al.  Bacteriology of empyema. , 1974, Lancet.

[187]  H. Feldman.  Streptococci and Streptococcal Diseases: Recognition, Understanding and Management , 1973 .

[188]  G. Koshi,et al.  Lancefield group F streptococci causing liver abscess and empyema. , 1971, The Indian journal of medical research.

[189]  G. Glantz,et al.  Pyogenic Liver Abscess Due to Microaerophilic Streptococci , 1967, Annals of surgery.

[190]  J. Koepke.  MENINGITIS DUE TO STREPTOCOCCUS ANGINOSUS (LANCEFIELD GROUP F). , 1965, JAMA.

[191]  O. Guthof.  [Pathogenic strains of Streptococcus viridans; streptocci found in dental abscesses and infiltrates in the region of the oral cavity]. , 1956, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale.